Dallas man sentenced 18 years for running violent drug ring at local hotel
A Dallas man was sentenced to 18 years in federal prison for running a violent drug-trafficking operation out of a local hotel.
The operation, based at the BuZen Suites Hotel, distributed various drugs including fentanyl, heroin, and methamphetamine 24/7.
Violent acts, including beatings and assaults, were common occurrences within the drug conspiracy.
DALLAS - A Dallas man was sentenced to 18 years in federal prison today for his role in a violent drug-trafficking conspiracy operated from a local Dallas hotel.
Local perspective
Kenneth Ray Peters, 44, of Dallas and multiple codefendants utilized rooms at the BuZen Suites Hotel located at 2030 W. Northwest Highway, Dallas, Texas to distribute quantities of fentanyl, heroin, cocaine, methamphetamine, marijuana, and other drugs.
In January 2025, Peters pled guilty to his role in the conspiracy, and today, he was sentenced to 216 months' imprisonment by Senior U.S. District Judge Barbara M. G. Lynn.
The drug conspiracy continued throughout 2022 and into March 2023.
Court records revealed that Peters and other coconspirators utilized a serving station inside multiple hotel rooms that held quantities of various drugs, drug paraphernalia and digital scales to distribute drugs to customers 24 hours a day, seven days a week.
According to court documents, a security camera was installed in the corner of the rooms that recorded the events each day.
Other coconspirators inside the rooms were paid to fill capsules with powdered fentanyl and cut and prepare other drugs for distribution.
Photographs were introduced during court hearings that captured cash, drugs, and other drug trade tools.
Peters admitted in court documents that violent acts committed by members of the conspiracy were common at the hotel, including multiple beatings, the pistol whipping of a customer, and the use of a lighter to burn the foot of a female customer who had passed out on the hotel room floor after ingesting drugs she had purchased in the room.
Court records show that on April 19, 2023, law enforcement agents executed multiple search warrants at the hotel.
Agents recovered distribution quantities of methamphetamine, powder and crack cocaine, heroin, powdered fentanyl, and counterfeit M30 pills that contained fentanyl, morphine, hydrocodone, Alprazolam and multiple kilograms of marijuana.
Officers also recovered multiple handguns, one AK-47 rifle, one AR-15 rifle, body armor, multiple digital scales, syringes, and other items consistent with drug distribution.
Dig deeper
Other codefendants charged in Peters' indictment have already been sentenced by Senior U.S. District Judge Lynn.
In December 2024, codefendant Derrick Alan Richardson was sentenced to 54 months in prison.
In January 2025, codefendant Antoine Marquin Thompson-Stevens was sentenced to 108 months in prison.
In March 2025, codefendants Keenan Bernard Allen a.k.a. "King" and Glenn Malcolm Blair a.k.a. "Slim" were sentenced to 240 months in prison.
On May 8, 2025, Allen's younger brother, Corey Lanard Allen, Jr., was sentenced to 192 months in prison.
The case was investigated by the Texas Department of Public Safety (DPS) and the Dallas Police Department's Narcotics Unit.
The Source
Information in this article was provided by the U.S. Attorney's Office of the Northern District of Texas.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a day ago
- Business Wire
ImmunityBio Announces Houston's Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA ® to Bladder Cancer Patients
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the Michael E. DeBakey Department of Veterans Affairs (VA) Medical Center in Houston recently became the first VA hospital in the Houston region and one of the first in the U.S. to provide treatment with ANKTIVA ® (nogapendekin alfa inbakicept-pmln) to a veteran with bladder cancer. ANKTIVA, the first of its kind immune-boosting, lymphocyte stimulating agent, is approved by the U.S. Food and Drug Administration (FDA) in combination with Bacillus Calmette-Guérin (BCG) for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). A 2024 study found military exposure to carcinogenic agents was associated with a higher risk for bladder cancer among veterans, making this treatment especially vital for those at the VA. Nationally recognized urologic oncologists at the Houston VA, Dr. Jeffrey Jones and Dr. Jennifer Taylor, were instrumental in bringing this novel treatment to veterans. They are strong advocates for advancing care for those battling bladder cancer. In addition, Dr. Jones, who is also affiliated with Baylor College of Medicine, led efforts to enroll the facility in ImmunityBio's Expanded Access Program (EAP) for rBCG. 'We are honored to see ANKTIVA reaching our nation's veterans,' said Dr. Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. 'Drs. Jones' and Taylor's leadership and commitment to innovation are exactly what's needed to expand access to transformative treatments like ANKTIVA across the VA system. This milestone at DeBakey underscores the real-world impact of our mission.' About ANKTIVA The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved in killing cancer cells. By activating NK cells, ANKTIVA overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response. ANKTIVA is a first-in-class IL-15 receptor superagonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15Rα, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA, which confers stability and longer half-life than recombinant or native IL-15, mimics the natural biological properties of the membrane-bound IL-15Rα, delivering IL-15 by dendritic cells and drives the activation and proliferation of NK cells with the generation of memory killer T cells that have retained immune memory against these tumor clones. The proliferation of the trifecta of these immune killing cells and the activation of trained immune memory results in immunogenic cell death, inducing a state of equilibrium with durable complete responses. ANKTIVA has improved pharmacokinetic properties, longer persistence in lymphoid tissues, and enhanced anti-tumor activity compared to native, non-complexed IL-15 in-vivo. ANKTIVA was approved by the FDA in 2024 for use in the United States with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (CIS) with or without papillary tumors. For more information, visit (Founder's Vision) and About ImmunityBio ImmunityBio is a vertically-integrated commercial stage biotechnology company developing next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. The Company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates NK cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit (Founder's Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding clinical trial data and potential results and implications to be drawn therefrom, treatment of patients at VA Medical Centers and in certain geographic locations and potential implications to be drawn therefrom, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents for the prevention or reversal of lymphopenia, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents across multiple tumor types and indications and for potential applications beyond oncology, potential regulatory pathways and the regulatory review process and timing thereof, the application of the Company's science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that has the potential to change the paradigm in cancer care, and ImmunityBio's approved product and investigational agents as compared to existing treatment options, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as 'anticipates,' 'believes,' 'continues,' 'goal,' 'could,' 'estimates,' 'scheduled,' 'expects,' 'intends,' 'may,' 'plans,' 'potential,' 'predicts,' 'indicate,' 'projects,' 'is,' 'seeks,' 'should,' 'will,' 'strategy,' and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties regarding the FDA regulatory submission, filing and review process and the timing thereof, (ii) risks and uncertainties regarding commercial launch execution, success and timing and market access initatives, (iii) risks and uncertainties regarding participation and enrollment and potential results from the expanded access clinical investigation program described herein, (iv) whether clinical trials will result in registrational pathways and the risks, (v) whether clinical trial data will be accepted by regulatory agencies, (vi) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (vii) potential delays in product availability and regulatory approvals, (viii) ImmunityBio's ability to retain and hire key personnel, (ix) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (x) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (xi) ImmunityBio's ability to successfully commercialize its approved product and product candidates, (xii) ImmunityBio's ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xiii) ImmunityBio's ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio's business are described under the heading 'Risk Factors' in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company's Form 10-Q filed with the SEC on August 5, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at ImmunityBio cautions you not to place undue reliance on any forward looking statements, which speak only as of the date hereof.
NBC Sports
2 days ago
- NBC Sports
After shooting at 345 Park Avenue, NFL recommends new security measures to teams
On July 28, a gunman who was apparently targeting the NFL killed four and seriously injured another before taking his own life. It could have been much worse. Now, the NFL has taken steps to protect against further violence, specifically with the league's 32 teams. Via Sports Business Journal, recently obtained a memo from the league to all teams. The memo recommends three changes to security protocols. First, the NFL suggests updated threat assessments at every team and league facility, in order to ensure that any risks are properly 'identified and mitigated.' Second, the NFL suggests the use of armed officers at all team and league facilities, whenever players or staff are present. Third, the NFL suggests the teams employ 'weapons screening' for anyone who enters a team or league facility, including walk-through magnetometers and X-ray scanners for bags. The memo acknowledges that 'these changes will affect day-to-day operations and require an investment of time, coordination, and resources,' but it accurately explains that 'there is no higher priority than the safety and security of our players, coaches, staff, and everyone who works in and around our facilities.' Arguably, some of these measures are overdue, given the NFL's profile and the inevitability of disgruntled former employees. As Chris Simms explained on the January 30 episode of PFT Live from Canton, he flew to Ohio with an employee of the league office who explained that they have been concerned about something like this happening for a while. In this specific case, the gunman drove from Las Vegas to Manhattan. He far more easily could have gone straight to the Raiders' headquarters. All teams need to be ready for another incident like this. There's another important, but unfortunate, point to make. None of the measures suggested by the league would have kept a man with an AR-15-style rifle from wreaking havoc at any team or league facility. The building where the attack happened had armed officers. But they were outgunned. That's the problem. Civilians have access to stronger and better guns than police officers carry. We know it's a political issue, even if it shouldn't be. The right to bear arms shouldn't include the right to bear overwhelming weaponry. The NFL is in a perfect position to stand up and make this case, loudly and clearlyL 'We had armed officers. It didn't matter. The armed officers had guns that didn't make the gun the killer had. Something must change.' It's a fair comment for the league to make. Because it's beyond obvious that something must change.
New York Post
2 days ago
- New York Post
LSU football's JT Lindsey surrenders after being accused of allowing murder suspects to stay in his dorm
LSU freshman running back JT Lindsey surrendered to campus police on Friday after a warrant was issued for his arrest on two felony counts of accessory after-the-fact to second degree murder, his attorney told WAFB-TV. He is accused of allowing two individuals — 17-year-old Shemell Jacobs and 18-year-old Keldrick Jordan — wanted on murder charges to stay in his LSU dorm room earlier this year, according to the arrest warrant obtained by the outlet. Jacobs and Jordan are accused of killing 17-year-old Corey Brooks in a fatal shooting in Alexandria, La., in May. 7 JT Lindsey surrendered to campus police on Friday. East Baton Rouge Parish Prison 7 JT Lindsey was a four-star recruit in the 2025 class. University Images via Getty Images LSU temporarily suspended Lindsey from all football activities until the resolution of his felony charges. His bond was set at $5,000 and he was released later on Friday, per WAFB-TV. 7 Shemell Jacobs and Keldrick Jordan are accused of second degree murder. Alexandria Police Department 'On 8/4/25 LSUPD was contacted by the U.S. Marshals Service, asking for help in locating the suspect,' the arrest warrant said. 'LSUPD was able to quickly locate Jacobs via surveillance footage and found him to be in and around Riverbend Hall. At approx. 1815 hrs LSUPD, along with assisting law enforcement agencies, were able to locate both Jacobs and Jordan in apartment 4071 of Riverbend Hall. Jaiden Lindsey is a resident of apartment 4071. 'In addition to this, Jacobs had Lindsey's LSU ID on his person and was able to provide Lindsey's personal pin code, which allowed him to come and go from the apartment and dorm building. When reviewing recorded surveillance footage, Lindsey can be seen in the dorm building with Jacobs and Jordan as far back as 7/24/25 and on multiple occasions, Jacobs and Jordan come and go without Lindsey, using his LSU ID to access the building.' 7 JT Lindsey catches a pass during LSU practice on Aug. 1, 2025. University Images via Getty Images Law enforcement officials said they found multiple firearms in the dorm room, including two AR-15 rifles, a Draco and a Glock, WAFB-TV reported. Lindsey's attorney, Kris Perret, told the outlet that Lindsey did not know Jacobs and Jordan were wanted for murder and that he was at football camp at the time. 7 JT Lindsey and LSU head coach Brian Kelly University Images via Getty Images 7 LSU has suspended JT Lindsey until his felony charges are resolved. WAFB Perret also said Lindsey is not alleged to be involved in 'the alleged crimes of the arrested individuals.' 'JT Lindsey is adamant that he is innocent of any alleged criminal misconduct and any allegations of wrongdoing against him,' Perret said in a statement. 'He is fully cooperating with authorities and looks forward to clearing his name as quickly as possible. …He was unaware that the individuals arrested had committed any crimes or that they had been accused of any crimes, or that they were wanted by the police for questioning when he allowed them to stay at his apartment. 'Had he known that the individuals were accused of any crimes or wanted by the police, he would not have allowed them into his apartment or associated with them in any manner.' 7 JT Lindsey University Images via Getty Images But the arrest warrant alleges that Lindsey did in fact know Jacobs and Jordan — both of whom he was friends with — were wanted for murder, citing an interview with 'an associate of Lindsey.' Lindsey was a four-star prospect in the 2025 class.
